Parkinson's Disease
JNNP 57:672-681, Marsden,C.D., 1994
Clinical Features of Dopamine Agonist Withdrawal Syndrome in a Movement Disorders Clinic
JNNP 84:130-135, Pondal, M.,et al, 2013
Pleuropulmonary Fibrosis After Long-term Treatment With the Dopamine Agonist Pergolide for Parkinson Disease
Arch Neurol 62:1290-1295, Tintner,R.,et al, 2005
Restless Legs Syndrome
NEJM 348:2103-2109, Earley,C.J., 2003
Dopamine Agonists: Their Role in the Treatment of Parkinson's Disease
JNNP 68;685-690, Brooks,D.J., 2000
Double-Blind Assessment of Potential Pergolide-Induced Cardiotoxicity
Neurol 36:993-995, Kurlan,R.,et al, 1986
Progressive Supranuclear Palsy:Clinical Features & Response to Treatment in 16 Patients
Ann Neurol 13:273-278, Jackson,J.A.,et al, 1983
Pergolide for the Treatment of Pituitary Tumors Secreting Prolactin or Growth Hormone
NEJM 309:704-709, Kleinberg,D.K.,et al, 1983
Treatment of Advanced Parkinson Disease With Pergolide
Neurol 31:675-682, Lieberman,A.,et al, 1981